The Developmental Funds are used to promote strategic cancer-research initiatives that the Cancer Center Director and other senior Cancer Center members have deemed important for the overall success of Cold Spring Harbor Laboratory's cancer research program. An important use of these funds has been to support new faculty recruited to the Cancer Center and to promote development of new technologies, either within the research programs or in the Cancer Center Shared Resources. CSHL has a dynamic research environment with a relatively high turnover of faculty, compared to the traditional university model. This provides an opportunity to recruit outstanding young scientists at the beginning of their careers. The Developmental Funds are a critical component for this recruitment and have provided support for investigators who have gone on to establish vibrant and productive cancer-research programs. These investigators have been successful in obtaining independent funding to continue their research. An extremely valuable source of funding, the Developmental funds give the Cancer Center Director the flexibility to support novel projects and incorporate new technologies and approaches. This also significantly enhances the opportunity for investigators to pioneer new and exciting research directions. The Developmental Funds strengthen the Cancer Center initiatives by allowing the recruitment of additional new faculty, whose inventive research approaches complement and expand upon current cancer-research programs.
Developmental funds at the Cold Spring Harbor Laboratory are used primarily for recruitment of new faculty whose research can expand existing cancer research programs and move into new directions to promote the Cancer Center's mission to understand the underlying mechanisms of cancer as a means to developing strategies for therapeutic intervention.
| Tiriac, Hervé; Belleau, Pascal; Engle, Dannielle D et al. (2018) Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer. Cancer Discov 8:1112-1129 |
| Forcier, Talitha L; Ayaz, Andalus; Gill, Manraj S et al. (2018) Measuring cis-regulatory energetics in living cells using allelic manifolds. Elife 7: |
| Naguib, Adam; Mathew, Grinu; Reczek, Colleen R et al. (2018) Mitochondrial Complex I Inhibitors Expose a Vulnerability for Selective Killing of Pten-Null Cells. Cell Rep 23:58-67 |
| Aberle, M R; Burkhart, R A; Tiriac, H et al. (2018) Patient-derived organoid models help define personalized management of gastrointestinal cancer. Br J Surg 105:e48-e60 |
| Bhagwat, Anand S; Lu, Bin; Vakoc, Christopher R (2018) Enhancer dysfunction in leukemia. Blood 131:1795-1804 |
| Khan, Jalal A; Maki, Robert G; Ravi, Vinod (2018) Pathologic Angiogenesis of Malignant Vascular Sarcomas: Implications for Treatment. J Clin Oncol 36:194-201 |
| Chen, Wei-Chia; Tareen, Ammar; Kinney, Justin B (2018) Density Estimation on Small Data Sets. Phys Rev Lett 121:160605 |
| Cheng, Derek; Tuveson, David (2018) Kras in Organoids. Cold Spring Harb Perspect Med 8: |
| Albrengues, Jean; Shields, Mario A; Ng, David et al. (2018) Neutrophil extracellular traps produced during inflammation awaken dormant cancer cells in mice. Science 361: |
| Cook, Natalie; Basu, Bristi; Smith, Donna-Michelle et al. (2018) A phase I trial of the ?-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma. Br J Cancer 118:793-801 |
Showing the most recent 10 out of 380 publications
